Insider Selling: Precigen, Inc. (NASDAQ:PGEN) SVP Sells $13,548.55 in Stock

Posted by Defense World Staff on Aug 21st, 2023

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) SVP Jeffrey Thomas Perez sold 8,741 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $1.55, for a total transaction of $13,548.55. Following the completion of the transaction, the senior vice president now directly owns 448,916 shares in the company, valued at $695,819.80. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Jeffrey Thomas Perez also recently made the following trade(s):

On Thursday, August 10th, Jeffrey Thomas Perez sold 8,956 shares of Precigen stock. The stock was sold at an average price of $1.21, for a total transaction of $10,836.76.
On Thursday, August 3rd, Jeffrey Thomas Perez sold 8,789 shares of Precigen stock. The stock was sold at an average price of $1.20, for a total transaction of $10,546.80.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $1.61 on Monday. The business’s 50 day moving average price is $1.26. Precigen, Inc. has a 1 year low of $0.81 and a 1 year high of $2.90.

Institutional Trading of Precigen

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc increased its holdings in Precigen by 10.6% in the 2nd quarter. Legal & General Group Plc now owns 70,487 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 6,777 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Precigen by 12.9% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 75,534 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 8,625 shares during the last quarter. Citigroup Inc. increased its holdings in Precigen by 29.5% in the 2nd quarter. Citigroup Inc. now owns 44,569 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 10,153 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Precigen by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 757,432 shares of the biotechnology company’s stock valued at $1,151,000 after purchasing an additional 10,907 shares during the last quarter. Finally, UBS Group AG increased its holdings in Precigen by 31.9% in the 3rd quarter. UBS Group AG now owns 47,068 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 11,381 shares during the last quarter. Institutional investors and hedge funds own 61.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Precigen in a research note on Tuesday, May 23rd. They issued a “neutral” rating on the stock. StockNews.com upgraded shares of Precigen to a “sell” rating in a report on Wednesday, August 16th. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Precigen in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Read Our Latest Research Report on PGEN

Precigen Company Profile

(Get Free Report)

Precigen, Inc is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.